Abstract: Objective To explore and compare the clinical efficacy of conventional chemotherapy combined with moxifloxacin or levofloxacin in the treatment of patients with multi-drug resistant pulmonary tuberculosis. Methods 98 patients with MDR-TB were selected from November 2019 to February 2021. According to the random digital table method, the patients in observation group were divided into two groups, 49 patients in observation group were treated with conventional chemotherapy and moxifloxacin, 49 cases in control group were treated with conventional chemotherapy and levofloxacin, and then compared after treatment. The clinical efficacy, immune function, focus absorption rate, sputum bacteria negative rate, cavity closure rate and adverse reactions were observed in the two groups. Results After treatment, the total effective rate of the observation group was 71.43%, which was significantly higher than that of the control group(P<0.05). After 18 months of treatment, the sputum negative conversion rate, lesion absorption rate and cavity closure rate of the observation group were 42.86%, 40.82% and 46.94%, respectively, which were significantly higher than those of the control group(P<0.05). After 18 months of treatment, the CD4⁺ in the observation group was(41.83±9.02)%, IgA was(4.08±0.62)g/L, IgG was(19.84±3.40)g/L,which were significantly higher than the control group. CD8⁺ was(29.83±5.62)%, which was significantly lower than that of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during the treatment(P>0.05). Conclusion The treatment of multi-drug resistant tuberculosis patients with conventional chemotherapy combined with moxifloxacin can significantly improve the immune function of patients, control the occurrence of adverse reactions, and the effects are accurate, which are worth popularizing and adopting in clinical practices.

Key words: moxifloxacin, levofloxacin, routine chemotherapy, multi drug resistant tuberculosis